BioLineRx Ltd.

BLRXTASEIL0011015182₪31M

Investment Thesis

Generates revenue primarily from licensing motixafortide/APHEXDA to partners for development and commercialization, earning upfront payments, milestones, and royalties. It also generated limited revenue from direct APHEXDA product sales prior to out-licensing.

Geographic Exposure

China51.68%

United States48.32%

Revenue Drivers

Motixafortide Asia licensing revenue

Licensing and support services for motixafortide development and commercialization.

CORE52.2%

Motixafortide ex-Asia licensing revenue

License granted to commercialize and develop motixafortide for non-solid-tumor indications.

CORE27%

APHEXDA direct product sales

Direct sales of APHEXDA prior to commercialization out-licensing.

SIGNIFICANT20.9%

End Markets

Pharmaceutical and biotechnology partners/licensees
Hospitals and transplant centers
Oncologists and hematologists
Clinical research institutions and investigators
Patients undergoing autologous stem-cell transplantation

Specializations

CXCR4 antagonist peptide therapeuticsOrphan drug designation strategy (FDA and EMA)Investigator-initiated clinical trialsIFRS 15 revenue allocation for bundled license-and-equity dealsPartner-led commercialization modelContract manufacturing and cGMP oversight+2 more

Activities

Drug discovery and in-licensing
Preclinical and clinical development
Out-licensing and alliance management
Regulatory strategy and lifecycle management
Contract manufacturing oversight and product supply